ClinicalTrials.gg
RecruitingNCT05916898LSSRUpdated Jun 23, 2023

The Lower Silesia Shockwave Registry

An observational study in Safety Issues and Efficacy, Self, sponsored by Regional Cardiology Center, The Copper Health Centre (MCZ),. Recruiting at 2 sites in Poland. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2023-06-23.

Sponsored by Regional Cardiology Center, The Copper Health Centre (MCZ), · Observational

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started May 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
400
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 154 studies in Coronary Artery Disease with a site in Poland — 33 open to participants now, 47 under way, 4 of them phase 3. Coronary Artery Disease · Poland.

Planned enrollment
23rd of 40
400 · median 585
Started
2022
with 5 others
Observational
40 of 154
11 open now
Primary completion
2026-05
later than 14 of 46 live
Registered
127th of 154
by date

Among the 154 studies in Coronary Artery Disease with a site in Poland, this one is the 23rd largest by planned enrollment of the 40 observational ones that give a count, is one of 6 that started in 2022, is one of 40 observational ones, reaches primary completion later than 14 of the 46 other live ones, and was the 127th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

33 of the 154 studies in Coronary Artery Disease with a site in Poland are open now. Recruiting first, the newest first:

27 more — sign in →

All 33 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 154 studies in Coronary Artery Disease with a site in Poland, or all of them as a file.
02

Study summary

Lower Silesia Shockwave Registry (LSSR), is a observational registry collecting all consecutive cases of percutaneous coronary intervention (PCI) performed with the support of shockwave intravascular lithotripsy in two cooperating cardiac centers (Department of Cardiology, The Copper Health Centre, Lubin Poland, and Department of Cardiology, Provincial Specialized Hospital in Legnica, Poland).

Read the detailed description

This study contains data from the Lower Silesia Shockwave Registry (LSSR), collecting all consecutive cases of percutaneous coronary interventions (PCI) performed with the support of shockwave intravascular lithotripsy from two cooperating cardiac centers (Department of Cardiology, The Copper Health Centre, Lubin Poland, and Department of Cardiology, Provincial Specialized Hospital in Legnica, Poland).

All patients involved in the study had a clinical indication for PCI based on current European Society of Cardiology (ESC) revascularisation guidelines, if necessary with the support of the local heart team.

Patients enrolled in the study had to meet one of two main inclusion criteria: The presence of a highly calcified, resistant lesion or a significantly under-expanded, previously implanted stent (regardless of the time of implantation). The lesion was defined as resistant after an unsuccessful high-pressure non-compliant (NC) balloon inflation (at least 20% under expansion; whit at least 16 atm.) The decision regarding initial lesion preparation was left to the operators' dissertation and did not imply a recruitment process. Patients meeting the inclusion criteria who initially underwent advanced debulking procedures (orbital or rotational atherectomy) were also recruited.

There were no angiographic exclusion criteria regarding lesion anatomy regarding the length, tortuosity, severity, or prior stent placement. Operators supported by angiography assessment with optional intravascular imagining (IVUS/OCT) determined the size of the S-IVL catheter and an appropriate number of pulses for optimal vessel preparation or management of an under-expanded coronary stent. Drug-eluting stent (DES) implantation or use of drug-eluting balloon catheters was left at the discretion of the operator.

The study had two primary endpoints- clinical success and safety outcome. The Clinical success was defined as an effective stent deployment or the optimization of previously not fully expanded stent (with less than \<20% in-stent residual stenosis) [ and the presence of Thrombolysis in Myocardial Infarction (TIMI) 3 flow at the end of the procedure.

Safety outcomes were defined as procedural final serious angiographic complications procedural (perforation, abrupt closure, slow flow or no-reflow, unstable ventricular arrhythmias) and device failure (inability to cross the lesion, malfunction, or rapture). Also, adverse cardiac and cerebrovascular events (MACCE) were recorded. The MACCE consisted of death, myocardial infarction, acute cerebrovascular events, and repeated revascularization of the target lesion. Clinical follow-up was obtained by professional medical staff - personally or by telephone contacts periodically every 6 months after the index procedure. The study has the approval of a local ethics committee ( Bioethical Committee at the Lower Silesian Medical Chamber - number of approval 04/BOBD/2022).

03

Conditions studied

  • Safety Issues
  • Efficacy, Self

Keywords

  • Percutaneous coronary interventions
  • Calcified Lesion
  • Shockwave intravascular lithotripsy
  • Stent under-expansion
  • Coronary artery diseases
  • lesion preparation
  • stent optimalization
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All-commers population with CAD treated by PCI performed with the support of shockwave intravascular lithotripsy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The presence of moderately to severely calcified lesions.
  • The presence of significant under-expansion (greater than 20% of the diameter) of the previously implanted stent.
  • Initial failure of the lesion preparation with either the NC balloon catheter or the atherectomy device.

Exclusion criteria

Exclusion Criteria:

  • Lack of patient consent
  • Target vessel dissection type 3 or higher according to spontaneous coronary artery dissection (SCAD) classification
  • Target vessel perforation due to previous unsuccessful lesion preparation
  • Pregnancy
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
400 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • S-IVL Intervention

    Patients with the presence of a highly calcified, resistant lesion or a significantly under-expanded, previously implanted stent (regardless of the time of implantation) were part of the study cohort. The lesion was defined as resistant after an unsuccessful high-pressure NC balloon inflation (at least 20% under-expansion; whit at least 16 atm.). The decision regarding initial lesion preparation was left to the operators' dissertation and did not imply a recruitment process. There were no angiographic exclusion criteria regarding lesion anatomy regarding the length, tortuosity, severity, or prior stent placement. Operators supported by angiography assessment with optional intravascular imagining (IVUS/OCT) determined the size of the S-IVL catheter and an appropriate number of pulses for optimal vessel preparation or management of an under-expanded coronary stent.

    Device: PCI with support of Shockwave Intravascular Lithotripsy

Interventions

  • DevicePCI with support of Shockwave Intravascular Lithotripsy

    Coronary artery angioplasty of the primary lesion or optimization of the previously implanted stent with the support of Shockwave Intravascular Lithotripsy device

06

What researchers measure

Primary outcomes

  1. The Clinical success

    Effective stent deployment or the optimization of previously not fully expanded stent (with less than \<20% in-stent residual stenosis) and the presence of Thrombolysis in Myocardial Infarction (TIMI) 3 flow at the end of the procedure.

    Time frame: Evaluation at the end of index hospitalization

  2. Incidence of Treatment-Emergent Adverse Events

    Safety outcomes were defined as procedural final serious angiographic complications procedural (perforation, abrupt closure, slow flow or no-reflow, unstable ventricular arrhythmias) and device failure (inability to cross the lesion, malfunction, or rapture).

    Time frame: Evaluation at the end of index hospitalization

Secondary outcomes

  1. Major adverse cardiac and cerebrovascular events (MACCE)

    The MACCE consisted of death, myocardial infarction, acute cerebrovascular events, and repeated revascularization of the target lesion.

    Time frame: Final assessment - 5 years after the initial hospitalization; followed by evaluation every 6 months from the end of the hospitalization until the final assessment (5 years).

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Rola P, Wlodarczak A, Kulczycki JJ, Barycki M, Furtan L, Szudrowicz M, Jastrzebski A, Pecherzewski M, Doroszko A, Lesiak M. Feasibility of the intravascular lithotripsy in coronary artery disease. Short-term outcomes of the Lower-Silesia Shockwave Registry. Kardiol Pol. 2021;79(10):1133-1135. doi: 10.33963/KP.a2021.0093. Epub 2021 Aug 20. No abstract available. PubMed 34415567 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for May 2026, 48 months after the start.

Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 48 months is close to that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2023
First posted
Jun 23, 2023
StartActual
May 1, 2022
Primary completionEst.
May 1, 2026
CompletionEst.
May 1, 2027
Last update
Jun 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05916898
Lead sponsor
Regional Cardiology Center, The Copper Health Centre (MCZ),
Collaborators
Provincial Specialized Hospital in Legnica
Responsible party
Adrian Włodarczak (M.D.; Ph.D. Assoc Prof., Regional Cardiology Center, The Copper Health Centre (MCZ),) — Principal investigator
First posted
Jun 23, 2023
Start date
May 1, 2022
Primary completion
May 1, 2026 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Jun 23, 2023

Study contacts

Adrian Włodarczak, M.D; Ph. D; Assoc Prof.
Contact
wlodarczak.adrian@gmail.com
+48768460300
Piotr Rola, M.D.; Ph.D.
Contact
piotr.rola@gmail.com
+48767211446

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion